Examining the effects of O blood products on patients with Myelodysplastic Syndrome
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes
This study is testing if using O blood products for transfusions helps or harms patients with Myelodysplastic Syndrome who need regular blood transfusions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | McMaster University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hamilton, Ontario) |
| Trial ID | NCT04859218 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates whether transfusions of O blood products impact patient outcomes in individuals diagnosed with Myelodysplastic Syndrome (MDS). The study focuses on patients who require regular red blood cell transfusions and aims to determine if receiving ABO non-identical red blood cells leads to adverse effects compared to ABO identical transfusions. By analyzing patient data and outcomes, the researchers hope to clarify the safety and efficacy of current transfusion practices for MDS patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of MDS who require regular red blood cell transfusions and have blood groups A, B, or AB.
Not a fit: Patients with blood group O or those requiring special transfusion products due to previous reactions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved transfusion protocols that enhance survival and reduce complications for patients with Myelodysplastic Syndrome.
How similar studies have performed: Previous studies have indicated potential risks associated with ABO non-identical transfusions, suggesting that this approach may yield significant insights into transfusion safety.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years of age 2. Diagnosis of MDS (Myelodysplastic syndrome ) without leukemia (IPSS-R classified or physician indicated either low-risk or intermediate-1) 3. Stable disease (as assessed by the patient's physician using MDS Stability Assessment Algorithm) 4. Blood group A, B, or AB 5. Requiring 2 RBC units at least every 6 weeks or less 6. Receiving transfusions in an outpatient setting Exclusion Criteria: 1. Unable to provide informed consent 2. Blood group O 3. Clinical requirement for special products because of reactions (e.g. washed or volume-reduced)
Where this trial is running
Hamilton, Ontario
- Juravinski Hospital and Cancer Centre — Hamilton, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Donald Arnold — McMaster University
- Study coordinator: Donald Arnold
- Email: arnold@mcmaster.ca
- Phone: 905 525-9140
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.